India’s pharmaceutical industry is nearing the milestone of 30 billion US dollars in exports, according to a recent industry report. The study highlights how Contract Research and Development Organisations (CRDMOs) and Global Capability Centers (GCCs) are driving the next wave of innovation, helping India evolve from a generics powerhouse into a global leader in advanced therapies and digital-first solutions.
Exports have grown significantly over the past decade, with India now supplying about 20 percent of global generics and 60 percent of vaccines. The CRDMO ecosystem is expanding rapidly, with global projections estimating the market could reach over 300 billion US dollars by 2028. GCCs, once seen as cost-saving units, have transformed into strategic innovation hubs, contributing to research, digital transformation, and global collaboration.
Industry leaders believe this shift from scale to science will strengthen India’s export potential and reputation as a hub for drug discovery, biotech research, and affordable healthcare solutions. The sector is also expected to play a central role in India’s long-term economic vision of becoming a 30–35 trillion US dollar economy by 2047.
In summary: India’s pharma exports are approaching 30 billion US dollars, with CRDMOs and GCCs powering innovation-led growth and positioning the country as a global leader in pharmaceutical innovation.
